Wall Street Zen lowered shares of Sotera Health (NASDAQ:SHC – Free Report) from a strong-buy rating to a buy rating in a research report released on Saturday morning,Wall Street Zen reports.
Several other analysts have also recently issued reports on the company. Weiss Ratings upgraded Sotera Health from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Thursday, October 8th. JPMorgan Chase & Co. reissued an “underweight” rating and set a $17.00 target price on shares of Sotera Health in a research note on Wednesday, October 14th. Piper Sandler reissued an “overweight” rating and set a $25.00 target price on shares of Sotera Health in a research note on Tuesday, September 8th. UBS Group set a $19.00 price target on Sotera Health in a report on Wednesday, June 24th. Finally, Citigroup increased their price target on Sotera Health from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Sotera Health presently has a consensus rating of “Moderate Buy” and an average price target of $21.38.
Get Our Latest Stock Report on Sotera Health
Sotera Health Trading Down 1.4%
Shares of SHC stock opened at $17.64 on Friday. The company has a debt-to-equity ratio of 3.33, a quick ratio of 2.55 and a current ratio of 2.80. The stock has a market capitalization of $5.03 billion, a P/E ratio of 21.05 and a beta of 1.85. The company has a 50 day moving average price of $18.64 and a 200 day moving average price of $17.22. Sotera Health has a fifty-two week low of $13.09 and a fifty-two week high of $19.85.
Sotera Health (NASDAQ:SHC – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.02. The firm had revenue of $321.38 million for the quarter, compared to the consensus estimate of $309.70 million. Sotera Health had a net margin of 13.44% and a return on equity of 40.12%. The firm’s revenue for the quarter was up 9.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.20 EPS. Sotera Health has set its FY 2026 guidance at 0.950-1.010 EPS. Equities research analysts predict that Sotera Health will post 0.87 EPS for the current fiscal year.
Insider Activity at Sotera Health
In other Sotera Health news, insider Michael P. Rutz sold 150,000 shares of the stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $18.84, for a total value of $2,826,000.00. Following the sale, the insider directly owned 334,279 shares of the company’s stock, valued at approximately $6,297,816.36. This represents a 30.97% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Chairman Michael B. Jr. Petras sold 850,000 shares of the firm’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $18.50, for a total transaction of $15,725,000.00. Following the completion of the sale, the chairman owned 3,969,393 shares in the company, valued at $73,433,770.50. The trade was a 17.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 1,294,515 shares of company stock valued at $23,999,528 in the last quarter. 15.36% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Sotera Health
Several large investors have recently bought and sold shares of SHC. BlackRock Inc. acquired a new stake in shares of Sotera Health during the 2nd quarter worth about $428,635,000. Sculptor Capital LP purchased a new stake in Sotera Health during the second quarter worth approximately $426,000,000. Jupiter Topco LLC purchased a new stake in Sotera Health during the second quarter worth approximately $149,137,000. Two Seas Capital LP purchased a new stake in Sotera Health during the second quarter worth approximately $103,590,000. Finally, Lakewood Capital Management LP acquired a new position in Sotera Health in the second quarter valued at approximately $70,638,000. Hedge funds and other institutional investors own 91.03% of the company’s stock.
Sotera Health Company Profile
Sotera Health Company (NASDAQ: SHC) is a healthcare services company focused on sterilization, laboratory testing and infection prevention. Its services support manufacturers and providers across the medical device, pharmaceutical, tissue, food safety and other healthcare-related industries.
The company operates through three primary businesses. Sterigenics provides outsourced sterilization services, including ethylene oxide, gamma irradiation and electron-beam processing. Nelson Labs offers laboratory testing, analytical services and consulting for medical devices, pharmaceuticals and other healthcare products.
Read More
- Five stocks we like better than Sotera Health
- Tesla’s Roadster Reveal Hints at 2 Much Bigger Moves
- The AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance Anyway
- Mr. Wonderful’s Test for AI Data Center Stocks: Power, Permits, and Tenants
- Alcoa Beat Earnings, But Can It Escape the Aluminum Bears?
Receive News & Ratings for Sotera Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sotera Health and related companies with MarketBeat.com's FREE daily email newsletter.
